News + Resources

Keep up with the latest

Featured

This Scientist Is Building Custom Gene-Editing Tools

This Scientist Is Building Custom Gene-Editing Tools

Epigenetic editors are a gentler form of gene editing

February 24, 2025

The Economist

Epigenetic editors are a gentler form of gene editing

February 24, 2025

Scribe Therapeutics Reports Preclinical Data Validating its CRISPR Genome Editing and Epigenome Modifying Technologies for Addressing Cardiometabolic Disease at American Heart Association (AHA) Scientific Sessions 2024

November 25, 2024

Scribe Therapeutics Reports Preclinical Data Validating its CRISPR Genome Editing and Epigenome Modifying Technologies for Addressing Cardiometabolic Disease at American Heart Association (AHA) Scientific Sessions 2024

November 25, 2024

CRISPR 2.0, the Next Generation

June 21, 2024

Aspen Ideas: Health

CRISPR 2.0, the Next Generation

June 21, 2024

The Age of CRISPR: Engineering the Future of Genetic Medicine

February 23, 2024

TEDxBerkeley

The Age of CRISPR: Engineering the Future of Genetic Medicine

February 23, 2024

All Stories

All
News
Press Releases
News

Scribe Therapeutics Sets Out to Write CRISPR Gene Editing’s Next Chapter

October 6, 2020

BioXconomy

Read Now
News

Doudna Inc.: How Cal scientist created a biotech startup engine

October 6, 2020

San Francisco Business Times

Read Now
News

The latest Jennifer Doudna startup launches with a Biogen partnership and eyes on big targets few CRISPR companies have chased

October 6, 2020

Endpoints News

Read Now
News

Scribe Therapeutics launches a platform for engineering CRISPR-based therapeutics

October 6, 2020

TechCrunch

Read Now
News

Jennifer Doudna’s New Gene Editing Company Launches With A $20 Million Round To Develop Genetic Medicines

October 6, 2020

Forbes

Read Now
News

C&EN’s Year in Pharma 2019

December 2, 2019

Chemical & Engineering News

Read Now
Press release

Scribe Achieves Milestone for In Vivo Program in Collaboration with Prevail Therapeutics, a part of Lilly’s Gene Therapy Division, and Announces ASGCT Joint Presentation on Self-Inactivating AAV Technology for Neurological and Neuromuscular Disorders

April 28, 2025

Read Now
Press release

Scribe Therapeutics to Unveil Latest Preclinical Data on Proprietary CRISPR Epigenetic Silencing Technology for LDL-C Lowering at the 2025 EAS Congress

April 23, 2025

Read Now
Press release

Scribe Therapeutics Presents Data on its Epigenetic Long-Term X-Repressor Technology at the 2025 Keystone Symposia on Precision Genome Engineering Conference

March 7, 2025

Read Now
Press release

Scribe Therapeutics to Participate in Upcoming Conferences

February 26, 2025

Read Now
Press release

Scribe Therapeutics Achieves Milestone for In Vivo Program in Collaboration with Sanofi

January 13, 2025

Read Now
Press release

Scribe Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

January 9, 2025

Read Now

Publications and presentations